Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

• Current expenditure on health, % of gross domestic product
• Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
• Annual growth rate of current expenditure on health, per capita, in real terms
• Out-of-pocket expenditure, % of current expenditure on health
• Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
• Physicians, Density per 1000 population (head counts)
• Nurses, Density per 1000 population (head counts)
• Total hospital beds, per 1000 population
• Curative (acute) care beds, per 1000 population
• Medical technology, Magnetic Resonance Imaging units, total, per million population
• Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Standard Report Structure

• Executive Summary
• Market Definition
• Macro-economic analysis
• Parent Market Analysis
• Market Overview
• Forecast Factors
• Segmental Analysis and Forecast
• Regional Analysis
• Competition Analysis

Market Taxonomy

The vulvodynia treatment market has been segmented on the following:

Specific Report Inputs

The analyst has checked the prevalence of vulvodynia among the women of 18 to 45 years of age. The main countries in every region have been gauged to check the prevalence rate in every country. The co-morbidity rate has also been considered country-wise. The annual treatment cost along with the volume consumed has been taken into consideration to come to the data in the report.